CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
Grant
US12589132B2
Kind: B2
Mar 31, 2026
Assignee
FIVE PRIME THERAPEUTICS, INC.
Inventors
Susannah D. Barbee, Thomas Brennan, Barbara Sennino
Abstract
The present disclosure provides methods of treating PD-L1 negative tumors, the methods comprising administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1).
CPC Classifications
A61K 38/1774
A61K 38/177
A61K 38/00
A61P 35/00
G01N 33/57492
G01N 2333/70532
G01N 2800/52
C12Q 2600/106
C12Q 2600/158
C12Q 1/6886
C07K 14/70532
C07K 2319/30
Filing Date
2020-02-21
Application No.
17432640
Claims
22